1. TMCI faces allegations of misleading shareholders about product demand. 2. Competition negatively impacted demand for TMCI's Lapiplasty system. 3. Declining revenue prompted TMCI to hasten alternative product development. 4. Class period for alleged malpractice is May 8, 2023 - May 7, 2024. 5. Investors can participate in the class action with no fees.
The allegations against TMCI may lead to decreased investor confidence. Historically, legal issues can significantly affect stock prices, as seen in similar cases when companies faced fraud allegations.
The class action reflects serious allegations that can deter investment and influence TMCI's market perception.
The nature of class action lawsuits often leads to prolonged uncertainty about a firm's financial health and could impact its performance well into the future.
The Gross Law Firm issues the following notice to shareholders of Treace Medical Concepts, Inc. (NASDAQ: TMCI).
Shareholders who purchased shares of TMCI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
May 8, 2023 to May 7, 2024
The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) competition impacted the demand for and utilization of its primary product, the 3D bunion correction system, the "Lapiplasty"; (2) as a result, Treace Medical's revenue declined and the Company needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function); and (3) defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
June 10, 2025 - Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/treace-medical-concepts-inc-loss-submission-form-2/?id=148433&from=4
Once you register as a shareholder who purchased shares of TMCI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is June 10, 2025. There is no cost or obligation to you to participate in this case.
The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: info@grosslawfirm.com
Phone: (646) 453-8903
The Gross Law Firm